Case Study: Theranos

1159 Words3 Pages

Theranos is a controversial health technology company that had provided medical diagnostic testing to consumers through the convenience of Theranos’ valuable partnership with Walgreens, and a unique vision of changing the healthcare industry. Theranos’ unique vision was to provide accurate and fast results in order to stop the onset of asymptomatic diseases (Rago 2013). Their key value proposition is aimed at proliferating the speed and accuracy of these diagnostic tests through automations which will limit human error and eliminate the need for multiple lab tests. Theranos primarily sought to perform these “accurate” tests with only trace amounts of blood from patients (Rago 2013). However, Theranos was not able to produce accurate results …show more content…

Although Theranos originally had good intentions and visionary goals of providing increased accessibility of testing to consumers, they were ultimately unsuccessful due to the inaccuracies of their test procedure, invalidating their other value propositions. Theranos’ visionary goal was to provide easier accessibility of testing for patients through their partnership with Walgreens. Theranos’ vision allowed them to capitalize on the growing retail clinic trends. The advantages of retail clinics and testing in pharmacies allow the convenience of patients with minor medical conditions to access patient care during inconvenient times, and as a result become increasingly popular (Dalen 2016). Retail clinics treat a range of acute conditions by PAs and NPs where only less than 5% of patients have conditions that fall beyond their scope (Dalen 2016). Theranos is taking the business model of retail clinics but applying it to in vitro testing. Theranos was highly successful in their goal of promoting the convenience of accessibility to tests for patients. However, due to the many controversies surrounding Theranos including the inaccuracies of tests, Walgreens eventually terminated …show more content…

This dilution process may potentially cause an underestimation of the test results leading to potential error. Theranos diagnostic testing was assessed when sixty individuals participated in a cohort, comparative study where Theranos finger pricking blood test was compared to a venipuncture blood draw testing biological molecule levels and different blood cell counts to a normalized reference range (Kidd et al. 2016). Figure 1 shows all of the results from Theranos that tested outside of its reference range from the 60 participants. Theranos was 1.6 times more likely to test outside of its normal reference range compared to other diagnostic testing laboratories in areas such as 5% out of range difference in RBC counts and lipid molecules including 10% difference for LDL and 40% difference for HDL (Kidd et al. 2016). These discrepancies demonstrate that there are high variability in Theranos sample collection and procedural data collection analysis which inhibits the usefulness of their automated systems limiting human error, speedy test results, and low test costs. The value in diagnostic testing revolves around the actual

Open Document